Protara Therapeutics with ticker code (TARA) have now 3 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 50 and 37 calculating the average target price we see 45.67. With the stocks previous close at 24.68 this would indicate that there is a potential upside of 85.0%. There is a 50 day moving average of 22.35 while the 200 day moving average is 23.42. The market cap for the company is $258m. You can visit the company’s website by visiting: http://www.protaratx.com
Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics and changed its name to Protara Therapeutics in May 2020. Protara Therapeutics is based in New York, New York.